House of Lords Business
Show full summary

Lord Mendelsohn to ask His Majesty's Government, further to the letter from the then Secretary of State for Health and Social Care on 6 September to Gemma Peters, Chief Executive of Blood Cancer UK, which states that “proceeding to patient access [to Evusheld is] considered to outweigh the risks of not providing this treatment in the current pandemic context”, what are the risks of not providing Evusheld.  HL2601

Question HL2601: tabled on 13 October 2022 and due for answer by 27 October 2022

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

Lord Mendelsohn to ask His Majesty's Government, further to the letter from the then Secretary of State for Health and Social Care on 6 September to Gemma Peters, Chief Executive of Blood Cancer UK, which states that “proceeding to patient access [to Evusheld is] considered to outweigh the risks of not providing this treatment in the current pandemic context”, what are the risks of not providing Evusheld.  HL2601
Legend for business item text
† Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.

Main Member

Lord Mendelsohn
Labour
Life peer